Clinical Roundup Cancer cells can use backup routes to fuel their growth, Van Andel Institute study finds September 19, 2025Vol.51 No.34
Drugs & Targets FDA approves gemcitabine intravesical system for non-muscle invasive bladder cancer September 19, 2025Vol.51 No.34
Drugs & Targets FDA approves Bosaya and Aukelso, denosumab biosimilars, for osteoporosis September 19, 2025Vol.51 No.34
Drugs & Targets FDA approves selumetinib for pediatric neurofibromatosis indication September 19, 2025Vol.51 No.34
Drugs & Targets FDA, Telix agree on NDA resubmission pathway for TLX101-CDx, an investigational agent for glioma imaging September 19, 2025Vol.51 No.34
Drugs & Targets EC grants conditional marketing authorization to Zemcelpro September 19, 2025Vol.51 No.34
Drugs & Targets VieCure, N-Power Medicine partner to expand clinical trial access in community oncology September 19, 2025Vol.51 No.34
Drugs & Targets Quest Diagnostics launches pharmacogenomics lab testing September 19, 2025Vol.51 No.34
Guest Editorial Reflections of a cancer scientistMaintaining the pace of novel technologies will lead to more efficient and less toxic medicines September 12, 2025Vol.51 No.33By Ze’ev Ronai
